Efficacy of Dupilumab in Patients with Atopic Dermatitis and Alopecia Areata: A Case Series
Clinical & Experimental Dermatology and Therapies · 2023
DOI: 10.29011/2575-8268.100211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Dermatology and Therapies, 2023.
Abstract (Originalsprache)
Alopecia areata is a non-scarring immune-mediated alopecia, more common in patients affected by atopic dermatitis, in which a pathogenetic role of Th2 cells has been suggested.In Italy, at present, patients suffering from severe atopic dermatitis (Erythema Area and Severity Index, EASI, score ≥ 24), nonresponding or non-eligible to cyclosporine-A, are successfully treated with dupilumab, a monoclonal antibody blocking interleukin-4 and interleukin-13 signalling pathway.Herein we report the cases of four patients, three adults and one child, affected by both atopic dermatitis and alopecia areata, who were treated with dupilumab.Two adult patients achieved a complete, or almost complete, and sustained response in their alopecia areata when treated with dupilumab.The paediatric patient experienced a temporary improvement, while the fourth patient did not respond to treatment.Our findings are consistent with existing literature that suggests a dysregulation of the Th2 axis, which includes interleukin-4 and interleukin-13, playing a role in the development of alopecia areata.However, further research is needed to confirm the efficacy of dupilumab in treating alopecia areata.
Zitieren
APA
(2023). Efficacy of Dupilumab in Patients with Atopic Dermatitis and Alopecia Areata: A Case Series. Clinical & Experimental Dermatology and Therapies. https://doi.org/10.29011/2575-8268.100211
Vancouver
Efficacy of Dupilumab in Patients with Atopic Dermatitis and Alopecia Areata: A Case Series. Clinical & Experimental Dermatology and Therapies. 2023. doi:10.29011/2575-8268.100211
BibTeX
@article{euvimed2023,
title = {Efficacy of Dupilumab in Patients with Atopic Dermatitis and Alopecia Areata: A Case Series},
journal = {Clinical & Experimental Dermatology and Therapies},
year = {2023},
doi = {10.29011/2575-8268.100211}
}
EUVIMED